For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers ...

For patients with genital psoriasis, apremilast improved genital Physician Global Assessment scores, itch, and quality of life with a tolerable safety profile.

Treatment with guselkumab among patients with psoriasis does not contribute to the risk for or progression of liver fibrosis.